[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Midwest Center for Metabolic and Cardiovascular Research\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":90},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100633712","assessing-two-coenzyme-q10-products-in-men-and-women-100633712",false,"NCT07530250","Assessing Two Coenzyme Q10 Products in Men and Women","A Randomized, Double-blind, Crossover Study to Assess the Relative Bioavailability of Two Coenzyme Q10 Products in Men and Women","Inclusion Criteria:\n\n1. Male or female, between 21 and 65 y of age.\n2. Individual has a BMI of 18.5 to 34.9 kg\u002Fm2.\n3. Individual has a score ≥7 on the Vein Access Scale.\n4. Individual is willing to discontinue any dietary supplement use for two weeks prior to visit 2 and throughout the end of the testing period.\n5. Individual is judged by the Investigator to be in generally good health on the basis of medical history and screening\u002Fbaseline measurements.\n6. Individual understands the study procedures, including maintaining usual physical activity pattern and refraining from vigorous physical activity for 24 h prior to each clinic visit requiring a blood draw. Signs forms documenting informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator.\n\nExclusion Criteria:\n\n1. Individual has any gastrointestinal condition that could potentially interfere with absorption of the study product (e.g., inflammatory bowel syndrome, celiac disease, history of gastric bypass surgery).\n2. Individual has a history or presence of clinically important endocrine (including Type 1 or Type 2 diabetes mellitus), cardiovascular (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, or stroke), pulmonary, renal, hepatic, or biliary disorders.\n3. Individual has had any major trauma or surgical event within 12 weeks prior to screening\u002Fbaseline (visit 1).\n4. Individual has a history or presence of cancer in the prior two years, except for non-melanoma skin cancer.\n5. Individual has uncontrolled hypertension (systolic blood pressure ≥160 mm Hg and\u002For diastolic blood pressure ≥100 mm Hg) at screening\u002Fbaseline (visit 1).\n6. Individual has a laboratory test result of clinical significance at screening\u002Fbaseline (visit 1) based on the judgment of the Principal Investigator or qualified designee.\n7. Individual has signs or symptoms of an active infection of clinical significance (e.g., urinary tract or respiratory) within five days prior to any test visit. If an infection occurs during the study period, test visits should be rescheduled until all signs and symptoms have been resolved for at least five days and, if antibiotics were prescribed, antibiotic therapy has been completed at least 7 days prior to the test visit.\n8. Individual has unstable use (defined as initiation or change in dose, agent, or regimen) of statin therapy within 3 months of visit 1.\n9. Individual uses medications or dietary supplements known to interfere with CoQ10 metabolism within 14 days prior to screening\u002Fbaseline (visit 1) and throughout the study period, including, but not limited to, lipid-lowering (stable dose of statin therapy is allowed), anti-hypertensive, hypoglycemic, anti-coagulant, and psychotherapeutic therapies. For all other medications, individual must be on a stable dose for at least 3 months prior to visit 1.\n10. Use of any prescription medication with known effects on appetite or weight (e.g., oral steroids, weight loss medications, etc.) within 3 months of visit 1. A stable dose of selective serotonin reuptake inhibitors ≥3 months is allowed.\n11. Individual has lost ≥4.5 kg (10 lbs.) in the previous 3 months.\n12. Use of tobacco\u002Fnicotine products (e.g., cigarette smoking, vaping, chewing tobacco) within 6 months of visit 1. Occasional use (defined as less than once per week) within 6 months of visit 1 is allowed but requires that the participant refrain for 24 hours prior to and during test visits.\n13. Individual follows a restricted diet (e.g., vegetarian, vegan, Atkins, etc.).\n14. Individual is a female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period.\n15. Individual has a known allergy or sensitivity to any ingredients in the study products or standardized meals\u002Fsnacks.\n16. Individual has been exposed to any non-registered drug product within 30 days of the prior to screening\u002Fbaseline (visit 1).\n17. Individual has a current or recent history (past 12 months of screening\u002Fbaseline) or strong potential for illicit drug or excessive alcohol intake defined as \\>14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1.5 oz hard liquor).\n18. Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.",true,"ALL","21 Years","65 Years",{"count":21,"type":22},24,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to compare the relative bioavailability of coenzyme Q10 (CoQ10) from acute administrations of a CoQ10 product designed for enhanced absorption versus a standard CoQ10 product in healthy men and women. Participants will be asked to come to the clinical on five different occasions, including a screening visit (visit 1, -7 days), two test 1 visits (visits 2 and 3, days 0 and 1), and two test 2 visits (visits 4 and 5, days 7 and 8). During the start of each test visit (visits 2 and 4), the participant will consume each study product with water and a standardized breakfast meal. Then, blood samples will be collected over a 10-hour period, and a standardized lunch, dinner, and snacks will be provided. The participant will return to the clinic the next morning for a blood draw 24 hours after the study product ingestion from the previous day. The same procedures will be repeated 7 to 14 days later with the other study product.",[28],"CoQ10 Blood Levels","RECRUITING","2026-06-11",{"date":32,"type":33},"2026-06-15","ACTUAL",{"date":35,"type":33},"2026-05-18",{"date":37,"type":22},"2026-07",{"name":39,"class":40},"Midwest Center for Metabolic and Cardiovascular Research","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100636487","assess-the-effects-of-replacing-foods-high-in-refined-carbohydrates-with-avocado-on-biomarkers-of-inflammation-100636487","NCT07566325","Assess the Effects of Replacing Foods High in Refined Carbohydrates With Avocado on Biomarkers of Inflammation.","Effects of Avocado Consumption on Inflammation and Insulin Sensitivity in Adults With Elevated High Sensitivity-C-reactive Protein (Hs-CRP): A Randomized, Controlled Crossover Trial","Inclusion Criteria:\n\n1. Male or female 21 - 74 years of age, inclusive;\n2. Baseline hs-CRP ≥2 to \\\u003C10 mg\u002FL;\n3. Central adiposity (waist circumference ≥35 inches in women and ≥40 inches in men);\n4. Body mass index 25.0 to 39.9 kg\u002Fm2;\n5. Normally active and judged by the Investigator to be in generally good health, based on medical history and screening measurements;\n6. Willing to consume daily study foods during each diet condition;\n7. Willing to maintain his\u002Fher regular physical activity pattern throughout the study period;\n8. Willing to follow test day instructions (refrain from consumption of alcoholic beverages and participation in vigorous physical activity for 24 hours and tobacco and caffeine for 1 hour prior to each test visit);\n9. No plans to change smoking, vaping, or other nicotine use habits during the study period; and\n10. Premenopausal women that are not using hormonal contraceptives must have a history of regular menstrual cycles (21-35 days per cycle) for at least 3 months prior to visit 1;\n11. Understands the study procedures and signs forms documenting informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator and is willing to complete study procedures.\n\nExclusion Criteria:\n\n1. Calculated energy needs of \\\u003C1800 kcal\u002Fd per the Mifflin-St. Jeor Equation, with an adjustment for energy expended in physical activity;\n2. Known metabolic disease (e.g., type 1 or type 2 diabetes, metabolic dysfunction-associated steatohepatitis, etc.);\n3. Laboratory test result(s) of clinical significance based on the judgment of the Principal Investigator or qualified designee, including fasting glucose ≥126 mg\u002FdL;\n4. Positive urine test for illicit drugs at visit 1;\n5. Clinical atherosclerotic disease;\n6. History or presence of clinically significant gastrointestinal, endocrine, renal, hepatic, hematologic, immunologic, dermatologic, pulmonary, pancreatic, neurologic, psychiatric, inflammatory or biliary disorder that, in the opinion of the Investigator, could interfere with the interpretation of the study results;\n7. History of cancer in the prior 2 years, except for non- melanoma skin cancer or carcinoma in situ of the cervix;\n8. Uncontrolled hypertension (systolic blood pressure ≥160 mm Hg and\u002For diastolic blood pressure ≥100 mm Hg) at screening;\n9. Unstable use (defined as initiation or change in dose) of anti-hypertensive medication within 4 weeks of visit 1;\n10. Unstable use (defined as initiation or change in dose) of thyroid hormone replacement medication within 12 weeks of visit 1;\n11. Use of beta-adrenergic blockers and\u002For high-dose (\\>25 mg\u002Fd) thiazide diuretics within 4 weeks of visit 1;\n12. Use of diabetes medications including glucagon-like peptide-1 (GLP-1) receptor agonists, GLP-1\u002Fglucose-dependent insulinotropic polypeptide (GIP) receptor agonists, alpha-glucosidase inhibitors, biguanides and biguanide combinations, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides and sulfonylureas and combination sulfonylureas within 4 weeks of visit 1;\n13. Unstable use (defined as initiation or change in dose, agent, or regimen) of statins within 4 weeks of visit 1;\n14. Use of lipid-altering drugs other than statins including, but not limited to bile acid sequestrants, cholesterol absorption inhibitors, or fibrates within 4 weeks of visit 1;\n15. Use of any prescription medication with known effects on inflammation (e.g., colchicine, systemic corticosteroids) within 4 weeks of visit 1;\n16. Frequent use (≥4 doses\u002Fweek) of non-steroidal anti-inflammatory drugs (NSAID) within 2 weeks of visit 2;\n17. Use of weight-loss drugs (including over-the-counter medications and\u002For supplements) or participation in a structured weight loss program within 4 weeks prior to visit 1;\n18. Unstable use (initiation or change in dose) within 4 weeks of visit 1 of sex hormones. Multiphasic hormonal contraceptives in which the amount of sex hormone in the active pill varies by week (i.e., biphasic, triphasic, quadriphasic) are considered unstable doses of sex hormones and are exclusionary;\n19. History of bariatric surgery or plans to have any surgery during the study;\n20. History of any major trauma or major surgical event within 2 months of visit 1;\n21. Use of herbs or dietary supplements that may affect lipid metabolism, including but not limited to omega-3 fatty acid supplements with \\>500 mg of eicosapentaenoic acid (EPA) and\u002For docosahexaenoic acid (DHA), niacin (or its analogs) at doses \\>200 mg\u002Fd, sterol\u002Fstanol products, dietary fiber supplements, red rice yeast supplements, garlic supplements, and soy isoflavone supplements within 2 weeks of visit 2;\n22. Use of herbs and dietary supplements that may affect carbohydrate metabolism, including chromium picolinate, ginseng, cinnamon (as a supplement) and starch blockers within 2 weeks of visit 2;\n23. Recent weight change of ±4.5 kg (\\~10 lbs.) within 3 months prior to visit 1;\n24. Has signs and symptoms of an active infection of clinical significance or has taken antibiotics within 5 days prior to any visit (washout is permitted by re-scheduling of the clinic visit);\n25. Extreme dietary habits (e.g., vegan, very low carbohydrate);\n26. History of an eating disorder (e.g., anorexia, bulimia nervosa, or binge eating) either diagnosed by a health professional or self-reported;\n27. Female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period;\n28. Known allergy, sensitivity, or intolerance to any components of the study foods;\n29. Exposed to any non-registered drug product within 4 weeks of visit 1;\n30. Currently participating in another research study;\n31. Use of hemp\u002Fmarijuana products within 12 months of visit 1. Occasional use (e.g., once or twice a month) within 12 months of visit 1 is allowed but requires at least a 14-day washout prior to visit 2 and the participant must be willing to refrain from use during the study;\n32. Current or recent history (past 12 months of screening) or strong potential for illicit drug or alcohol abuse. Alcohol abuse will be defined as \\>14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1.5 oz hard liquor); and\n33. Condition the Investigator believes would interfere with his or her ability to provide informed consent or comply with the study protocol, or which might confound the interpretation of the study results or put the person at undue risk.","74 Years",{"count":51,"type":22},38,[25],"The objective of this trial is to assess the effects of replacing foods high in refined carbohydrates, particularly added sugars, with avocado (isocaloric substitution) on biomarkers of inflammation and insulin sensitivity in adults with elevated hs-CRP and central adiposity. Eligible participants will complete two 4-week interventions (1 avocado\u002Fd and control) separated by a 2-week washout phase. Participants will complete a total of 7 clinic visits including one screening visit (visit 1, -7 days), one baseline visit (visit 2, day 0), two visits during each 4-week diet condition (visit 3 \\& 6 on day 21 and visits 4 \\& 7 on day 28), and one visit at the conclusion of the washout phase\u002Fstart of the second condition (visit 5, day 0).",[55,56,57],"Overweight (BMI > 25)","Obesity (BMI>30)","Hs-CRP","NOT_YET_RECRUITING","2026-05-04",{"date":61,"type":33},"2026-05-08",{"date":63,"type":22},"2026-05-11",{"date":65,"type":22},"2026-12",{"name":39,"class":40},2,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":16,"sex":17,"minAge":75,"maxAge":49,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":41},"100632513","assessing-the-effects-of-corn-and-avocado-oils-on-the-cardiometabolic-risk-factor-profile-100632513","NCT07514663","Assessing the Effects of Corn and Avocado Oils on the Cardiometabolic Risk Factor Profile","A Randomized, Double-Blind, Controlled Feeding, Crossover Trial to Assess the Effects of Corn and Avocado Oils on the Cardiometabolic Risk Factor Profile in Men and Women","Inclusion Criteria:\n\n1. Male or female 18 - 74 years of age, inclusive.\n2. Body mass index ≥18.5 and \\\u003C35.0 kg\u002Fm2.\n3. Fasting non-HDL-C level ≥125 mg\u002FdL and \\\u003C225 mg\u002FdL.\n4. Fasting TG level \\\u003C500 mg\u002FdL.\n5. Vein access scale score of 7-10.\n6. Judged by the Investigator to be in generally good health, based on medical history and screening measurements.\n7. Calculated energy needs of ≥1800 kcal\u002Fd per the Mifflin-St Jeor Equation, with an adjustment for energy expended in physical activity.\n8. Willing to consume only study-related foods\u002Fbeverages during each 21-d condition and visit the clinic each weekday morning during this time.\n9. If a smoker, subject has no plans to change smoking habits during the study period.\n10. Understands and is willing to complete the study procedures, including maintaining usual physical activity pattern and refraining from vigorous physical activity for 24 h prior to each clinic visit requiring a blood draw. Signs forms documenting informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator.\n\nExclusion Criteria:\n\n1. Known allergy or sensitivity to study product or any ingredients of the study product or assigned meals\u002Fsnacks\u002Fbeverages provided.\n2. Abnormal laboratory test results of clinical significance. One retest may be allowed on a case-by-case basis at the discretion of the Investigator.\n3. Fasting blood glucose ≥126 mg\u002FdL at screening or known type 1 or type 2 diabetes mellitus.\n4. Uncontrolled hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg as defined by the average blood pressure. One re-test will be allowed on a separate day prior to visit 2 (day 0) for participants whose blood pressure exceeds either of these cut points at visit 1 (day -7).\n5. Atherosclerotic cardiovascular disease, including any of the following: clinical signs of atherosclerosis including peripheral arterial disease, abdominal aortic aneurysm, carotid artery disease (symptomatic \\[e.g., myocardial infarction, angina, transient ischemic attack or stroke of carotid origin\\] or \\>50% stenosis on angiography or ultrasound) or other forms of clinical atherosclerotic disease (e.g., renal artery disease).\n6. History or presence of a clinically significant gastrointestinal, endocrine, renal, hepatic, hematologic, immunologic, dermatologic, pulmonary, pancreatic, neurologic, psychiatric, inflammatory or biliary disorder that, in the opinion of the Investigator, could interfere with the interpretation of the study results.\n7. History or presence of cancer in the prior two years, except for non-melanoma skin cancer.\n8. Unstable use (defined as initiation or change in dosage) of anti-hypertensive medication within 12 weeks of visit 1 (day -7).\n9. Use of beta-adrenergic blockers and\u002For high-dose (\\>25 mg\u002Fd) thiazide diuretics within 4 weeks of visit 1 (day -7).\n10. Unstable use (defined as initiation or change in dose) of any thyroid hormone replacement within 12 weeks of visit 1 (day -7).\n11. Unstable use (defined as initiation or change in dosage, agent, or regimen) of statin medication within 12 weeks of visit 1 (day -7).\n12. Use of any medications intended to alter the lipoprotein lipid profile, other than statins, including but not limited to, bile acid sequestrants, cholesterol absorption inhibitors, fibrates, prescription omega-3 fatty acid drugs (e.g., icosapent ethyl), or proprotein convertase subtilisin\u002Fkexin 9 (PCSK9)-targeted therapy within 12 weeks of visit 1 (day -7).\n13. Use of any foods or dietary supplement that might alter lipid metabolism, including but not limited to, omega-3 fatty acid dietary supplements (e.g., flaxseed, fish, or algal oils) or fortified foods, sterol\u002Fstanol products; red rice yeast supplements; garlic supplements; soy isoflavone supplements; and niacin or its analogues at doses \\>200 mg\u002Fd (or others at the discretion of the Investigator) within 2 weeks of visit 2 (day 0). A stable dose of any dietary fiber supplement, including Metamucil® or viscous fiber-containing supplement per day, is allowed.\n14. Use of diabetes medications, including α-glucosidase inhibitors, biguanides and biguanide combinations, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic polypeptide, meglitinides, sulfonylureas and sulfonylurea combinations, and thiazolidinediones, within 12 weeks of visit 1 (day -7).\n15. Use of dietary supplements that may affect carbohydrate metabolism, including chromium picolinate, ginseng, cinnamon (as a dietary supplement), and starch blockers within 2 weeks of visit 2 (day 0).\n16. Use of systemic corticosteroids within 4 weeks of visit 1 (day -7).\n17. Use of prescribed weight-loss drugs or programs within 12 weeks prior to visit 1 (day -7).\n18. Use of over-the-counter weight-loss medications, dietary supplements, or programs within 2 weeks prior to visit 2 (day 0).\n19. Weight loss or gain \\>4.5 kg in the 3 months prior to visit 1 (day -7).\n20. Extreme dietary habits (e.g., very-low-carbohydrate, vegetarian, vegan diets) in the opinion of the Investigator.\n21. History of a diagnosed eating disorder (e.g., anorexia or bulimia nervosa).\n22. Active infection or use of antibiotics within 5 d of any blood draw to measure lipoprotein lipid levels \\[Condition 1, visits 1 through 4 (days -7 through 21) and Condition 2, visits 5 through 7 (days 0 through 21)\\]. For those with an active infection and\u002For using antibiotics, participants must wait at least 5 d after the infection is resolved or antibiotic use is complete. The condition will be extended for completion of the controlled feeding period in these cases.\n23. Female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period. The method of contraception must be recorded in the source document.\n24. Positive urine drug screen for illicit drugs at visit 1.\n25. Recent history of (within 12 months of screening; visit 1, day -7) or strong potential for alcohol or substance abuse. Alcohol abuse is defined as \\>14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1½ oz distilled spirits).\n26. Exposure to any non-registered drug product within 30 d prior to visit 1 (day -7).\n27. Any condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.","18 Years",{"count":77,"type":22},54,[25],"The goal of this clinical trial is to assess the effects of corn and avocado oils as part of controlled feeding diets on the cardiometabolic risk factor profile in men and women with mild-to-moderately elevated levels of non-high-density lipoprotein cholesterol (non-HDL-C). Participants will be asked to consume the controlled feeding diet for two separate 21 day conditions, and will consume their regular diet for a 21 day washout period between the two conditions. Additionally, participants will be asked to come into the clinic on 7 different occasions, including one screening visit (visit 1, -7 days), one baseline visit (visit 2, day 0), two visits during each 21-d diet condition (visits 3 \\& 6, day 19 and visits 4 \\& 7, day 21), and a visit at the conclusion of the washout phase\u002Fstart of the second diet condition (visit 5, day 0).",[81],"Hypercholesterolemia","2026-04-14",{"date":84,"type":33},"2026-04-17",{"date":86,"type":33},"2026-04-10",{"date":88,"type":22},"2026-09",{"name":39,"class":40},""]